Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 3OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Neurofibromatosis 1 6Neoplasm Metastasis 6Solid Tumours 5Neoplasms 5Melanoma 5Neurofibroma, Plexiform 4Lung Neoplasms 3Colorectal Neoplasms 3Breast Neoplasms 2Biliary Tract Neoplasms 2Uveal Melanoma 1Solid Tumors 1Renal Insufficiency 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Muscle Invasive Bladder Cancer 1Locally Advanced or Metastatic Solid Tumors 1Kidney Neoplasms 1Healthy Volunteers Pharmacokinetic Study 1Disease Progression 1Differentiated Thyroid Cancer 1Colonic Neoplasms 1Advanced Non Small Cell Lung Cancer 1Advanced Cancer 1

Interventions

Gemcitabine 205130-nm albumin-bound paclitaxel 84Albumin-Bound Paclitaxel 57pembrolizumab 43Fluorouracil 41Leucovorin 34Oxaliplatin 33Capecitabine 25Nivolumab 22Irinotecan 19Bevacizumab 17Paclitaxel 16Cyclophosphamide 15Cetuximab 15Taxes 13Erlotinib Hydrochloride 13Drug Therapy 13Carboplatin 12irinotecan sucrosofate 11Injections 10Cisplatin 9fludarabine 8ALT-803 8spartalizumab 7olaparib 7avelumab 7Pemetrexed 7Docetaxel 7ruxolitinib 6TH 302 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pancreatic Neoplasms × AZD 6244 × Clear all
NCT00372944 2014-08-13

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

AstraZeneca

Phase 2 Completed
70 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡